A Trail of Fluzoparil in Combination With Temozolomide in Patients With

See also
Status	Clinical Trial	Phase
Completed	`NCT02768389` - Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma	Early Phase 1
Completed	`NCT03679754` - Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102	Phase 1
Completed	`NCT01250470` - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma	Phase 1
Terminated	`NCT03927222` - Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma	Phase 2
Recruiting	`NCT03897491` - PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma	Phase 2
Recruiting	`NCT03587038` - OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma	Phase 1
Completed	`NCT01922076` - Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	Phase 1
Recruiting	`NCT04391062` - Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma	Phase 2
Active, not recruiting	`NCT03661723` - Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma	Phase 2
Active, not recruiting	`NCT02655601` - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001	Phase 2
Active, not recruiting	`NCT03493932` - Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade	Phase 1
Terminated	`NCT02709889` - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors	Phase 1/Phase 2
Completed	`NCT03018288` - Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)	Phase 2
Not yet recruiting	`NCT05698524` - A Study of Temodar With PCI-24781 for Patients With Recurrent Glioma	Phase 1
Withdrawn	`NCT03980249` - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells	Early Phase 1
Withdrawn	`NCT02876003` - Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma	Phase 2
Completed	`NCT02905643` - Discerning Pseudoprogression vs True Tumor Growth in GBMs
Recruiting	`NCT01985087` - A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70	Phase 1/Phase 2
Withdrawn	`NCT01622764` - 89Zr-RO5323441 PET Imaging in Glioblastoma	Phase 2
Recruiting	`NCT01765088` - A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas	Phase 3

NCT number	NCT04552977
Study type	Interventional
Source	Shandong Cancer Hospital and Institute
Contact	Jinming Yu, Ph.D, M.D
Phone	13806406293
Email	sdyujinming@126.com
Status	Not yet recruiting
Phase	Phase 2
Start date	September 2020
Completion date	August 2022

A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms